Servo-n HFOV Study: Safety and Performance in Neonates and Infants

Servo-n High-Frequency Oscillatory Ventilation in Clinical Practice: A Prospective, Observational, Single-arm and Multi-center Study

The purpose of this study is to evaluate the safety and performance of High-Frequency Oscillatory Ventilation (HFOV) modes of the Servo-n ventilator in neonates and infants, by using a prospective, observational, single-arm (i.e., non-controlled) and multi-center Post-Market Follow-up (PMCF) study design. HFOV treatment will be evaluated by assessing ventilation and oxygenation variables, and safety will be evaluated by documentation of device related adverse events.

Study Overview

• Status: Active, not recruiting
• Conditions: Elective HFOV for Respiratory Failure in Neonates/Infants; Rescue HFOV in Neonates and/Infants With Refractory Respiratory Failure Under Conventional Therapy
• Intervention / Treatment: Device: Servo-n HFOV modes

Detailed Description

The purpose of this study is to evaluate the safety and performance of HFOV modes of the Servo-n ventilator in neonates and infants. This is a prospective, observational, single-arm (i.e., non-controlled) and multi-center PMCF study in neonates and infants between 0.3 to 8 kg. All study procedures are within each hospital's routine clinical practice.The primary endpoints includes variables which are routinely used per clinical practice for assessing the status of patient's ventilation and oxygenation, respectively. Secondary endpoints are used to evaluate safety of Servo-n HFOV during its use by assessing rates of adverse event/ device deficiencies related to the Servo-n HFOV device, and by assessing rates of mortality, Bronchopulmonary Dysplasia (BPD) and Retinopathy at Intensive Care Unit (ICU) discharge. Data collection will take place up to 24 hours prior to HFOV treatment, during HFOV and up to ICU discharge. Additional general data such as ventilator settings, reasons for initiating/terminating HFOV treatment and demographics will also be recorded.

• Study Type: Observational
• Enrollment (Estimated): 75

Contacts and Locations

Study Locations

• France
  • Montpellier, France
    • CHU Montpellier-Arnaud de Villeneuve
  • Paris, France
    • Antoine-Béclère Hospital
• Poland
  • Poznan, Poland
    • Poznan University of Medical Sciences
• Switzerland
  • Geneva, Switzerland
    • University Hospital of Geneva (HUG)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Both preterm and term (0.3-8 kg) neonatal/infant patient group requiring HFOV treatment. Subjects on elective HFOV and rescue HFOV, will be enrolled from up to 10 sites in European countries.

Description

Inclusion Criteria:

• Provision of written informed consent by the patient's legally designated representative(s) (may be obtained as deferred consent up to 24 hours after HFOV initiation: valid for both elective and rescue HFOV patients)

• Patients eligible for HFOV ventilation with Servo-n:

  • Patient is either switched from conventional mechanical ventilation or HFOV with other device to Servo-n HFOV based on clinicians judgement (rescue HFOV). Note: the reason for the switch has to be that the patient failed to oxygenate or ventilate adequately with CMV or the other HFOV device

    ; OR

  • Patient was prior without or with any type of non-invasive respiratory support and is put on invasive HFOV treatment based on clinicians judgement (elective HFOV)
• Patient has not already been on HFOV in a previous episode, unless the etiology of respiratory failure has changed during the same hospitalisation. For example, initial HFOV treatment for RDS, second HFOV episode of NARDS of any etiology (will be enrolled as a new patient case). NOTE1: When a patient failed weaning on conventional ventilation within 6 hours, requiring to be put back on HFOV it will be counted as one HFOV episode (weaning failure) NOTE2: When a patient is temporarily put on conventional ventilation for transport or a surgical intervention, and will be put back to HFOV afterwards, it will be counted as one HFOV episode (HFOV paused).
• Patient has a body weight from 0.3 to 8.0 kg

Exclusion Criteria:

• Diagnosis of congenital diaphragmatic hernia
• Severe cardiac anomaly expected to need corrective surgery or catheter-based intervention within 30 days from birth
• Cyanotic heart disease
• Intracranial hemorrhage, Grade III or IV
• Congenital malformations with the exception of isolated lung hypoplasia
• Persistent pulmonary hypertension (PPHN) with a documented shunt on the level of the foramen ovale
• Bronchopulmonary Dysplasia (BPD) /Chronic Lung Disease (CLD)

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Servo-n HFOV treatment; As this study is single-armed (non-controlled), all patients in this study receive the same treatment, i.e. Servo-n HFOV treatment. There are however two subgroups, elective HFOV and rescue HFOV treatment	Device: Servo-n HFOV modes; Treatment with high frequency oscillatory ventilation with Servo-n device in accordance to Standard of Care

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of subjects that achieved and/or maintained target ranges for oxygenation, as measured by preductal Saturation of Peripheral Oxygen (SpO2).	Oxygenation response, elective HFOV patients	After Servo-n HFOV treatment, expected treatment duration 1-30 days
Proportion of subjects that achieved and/or maintained target ranges for ventilation as measured either by Partial Pressure of Carbon Dioxide (PCO2) (if available blood gas) or Transcutaneous Carbon Dioxide (TcCO2)	Ventilation response, elective HFOV patients	After Servo-n HFOV treatment, expected treatment duration 1-30 days
Proportion of subjects that maintained or improved values for oxygenation as measured by the SpO2/FiO2 ratio and/ or achieved target ranges for oxygenation (preductal SpO2)	Oxygenation response, rescue HFOV patients	After Servo-n HFOV treatment, expected treatment duration 1-30 days
Proportion of subjects that maintained or improved values, and/or achieved target ranges, for ventilation as measured either by PCO2 (if available blood gas) or TcCO2.	Ventilation response, rescue HFOV patients	After Servo-n HFOV treatment, expected treatment duration 1-30 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The occurrence of reported Servo-n HFOV device (including accessories) deficiencies and adverse device effects and serious adverse device effects (ADE and SADE)	Device deficiencies and adverse events	After Servo-n HFOV treatment, expected treatment duration 1-30 days
Patient outcome at ICU discharge	Events to be noted are: death caused by respiratory failure, death caused by circulatory failure, all-cause death, device related death, retinopathy and bronchopulmonary dysplasia	Through study completion (at ICU discharge), expected up to 120 days
Assessment of oxygenation status	Oxygen Saturation (SO2)	From available blood gas and at Baseline (-4h -2h, -1h, 0h), During HFOV (0h, 30min, 1h, 2h, 4h, 6h. etc every 6 h), Post HFOV (2h, 4h, 6h, 12h and 24h)
Assessment of ventilation status	Partial pressure of CO2 (PCO2)	From available blood gas and at Baseline (-4h -2h, -1h, 0h), During HFOV (0h, 30min, 1h, 2h, 4h, 6h. etc every 6 h), Post HFOV (2h, 4h, 6h, 12h and 24h)

Collaborators and Investigators

• Sponsor: Maquet Critical Care AB
• Collaborators: NAMSA; Paediatric and Neonatal Mechanical Ventilation (PNV) Consulting
• Investigators: Study Chair: Peter Rimensberger, Prof. MD, PNV consulting

Study record dates

Study Major Dates

• Study Start (Actual): July 15, 2024
• Primary Completion (Estimated): June 30, 2026
• Study Completion (Estimated): June 30, 2026

Study Registration Dates

• First Submitted: October 11, 2023
• First Submitted That Met QC Criteria: October 30, 2023
• First Posted (Actual): November 2, 2023

Study Record Updates

• Last Update Posted (Actual): April 21, 2026
• Last Update Submitted That Met QC Criteria: April 20, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Respiration Disorders; Respiratory Insufficiency
• Other Study ID Numbers: EVU-215176

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No